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Abstract
Background: The assessment of the impact of healthcare interventions may help commissioners
of healthcare services to make optimal decisions. This can be particularly the case if the impact
assessment relates to specific patient populations and uses timely local data. We examined the
potential impact on readmissions and mortality of specialist heart failure services capable of
delivering treatments such as b-blockers and Nurse-Led Educational Intervention (N-LEI).
Methods: Statistical modelling of prevented or postponed events among previously hospitalised
patients, using estimates of: treatment uptake and contraindications (based on local audit data);
treatment effectiveness and intolerance (based on literature); and annual number of hospitalization
per patient and annual risk of death (based on routine data).
Results: Optimal treatment uptake among eligible but untreated patients would over one year
prevent or postpone 11% of all expected readmissions and 18% of all expected deaths for
spironolactone, 13% of all expected readmisisons and 22% of all expected deaths for b-blockers
(carvedilol) and 20% of all expected readmissions and an uncertain number of deaths for N-LEI.
Optimal combined treatment uptake for all three interventions during one year among all eligible
but untreated patients would prevent or postpone 37% of all expected readmissions and a
minimum of 36% of all expected deaths.
Conclusion: In a population of previously hospitalised patients with low previous uptake of b-
blockers and no uptake of N-LEI, optimal combined uptake of interventions through specialist heart
failure services can potentially help prevent or postpone approximately four times as many
readmissions and a minimum of twice as many deaths compared with simply optimising uptake of
spironolactone (not necessarily requiring specialist services). Examination of the impact of different
heart failure interventions can inform rational planning of relevant healthcare services.
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Background
Heart failure has a survival rate worse than for many com-
mon cancers [1,2] and is responsible for 4% of all UK
deaths [3]. Hospital admissions are frequent [4-6], partly
preventable [7], and costly [8]. Apart from Angiotensin
Converting Enzyme (ACE) inhibitors or Angiotensin 2
(A2) antagonists, medical treatments reducing mortality
and readmissions in heart failure due to Left Ventricular
Systolic Dysfunction (LVSD) include b-blockers [9], and,
in New York Heart Association (NYHA) class III/IV
patients, spironolactone [10]. Non-pharmacological
"nurse-led" educational intervention (N-LEI) reduces
readmissions [11], and may also reduce mortality, partic-
ularly long-term [12]. N-LEI consists of multidisciplinary
interventions which may include: dietary advice, patient
and carer education about heart failure treatment and
management, education about recognition of signs of
decompensation and suitable action plans, medication
review by either a pharmacist or a doctor, exercise train-
ing, counselling, and follow-up contacts either at home,
or at a specialist clinic, or by telephone [11]. The typical
patient receiving N-LEI is one with a recent hospital
admission due to heart failure. The number of patient
contacts and the intensity of the intervention is greater at
the start of the programme (i.e. during the first few weeks)
and its overall duration is typically short term (i.e. up to
six months, but usually shorter).
Nearly all heart failure patients requiring hospital admis-
sion have advanced disease (NYHA class III/IV) [13] and
therefore usually require post-discharge introduction and
gradual up-titration of b-blockers over an average of four
follow-up appointments [14], usually under specialist
supervision [15-18]. Delivering N-LEI requires employ-
ment of appropriately trained and accredited nursing
staff. In practice the provision of both b-blockers and N-
LEI depends on the existence of specialist services, usually
in the form of a heart failure clinic run by specialist med-
ical and nursing staff [14], which may explain why inter-
ventions improving prognosis are sub-optimally used
[19].
Evidence-based medicine has greatly contributed to
rational decision-making in the treatment of individual
patients, but the delivery of interventions to populations
of patients is not always based on evidence [20]. Assessing
the expected impact of proposed interventions can sup-
port the rational planning of healthcare services and
inform health economic analysis. Several recent publica-
tions have assessed the potential incremental impact of
various cardiovascular interventions [21-25], on national
[21,22] or hypothetical [23-25], populations, using novel
and promising modelling techniques [26]. There is a need
to extend healthcare impact assessment to setting-specific
patient populations, using timely local data. This may
improve the accuracy and practical relevance of the assess-
ment, as local decision makers may prefer calculations
that use local population data. We therefore examined the
potential impact of increasing uptake of evidence-based
interventions on a population of heart failure patients
with history of previous hospitalisation in Stockport NHS
Trust, a UK district general hospital of Greater Manchester,
using local data on outcomes, and treatment uptake and
contraindication rates. The study hospital serves a
notional reference population of about 300,000 (or about
0.5% of the total UK population). In the study setting,
about 85% of all patients with an emergency medical
admissions are from Stockport, a population with slightly
better health characteristics to the general UK population,
with a Standardised Mortality Ratio from all causes (all
ages) of 96 (95% CI 94–98)[27]. At the time of the study,
the introduction of specialist heart failure services in the
local health economy was under consideration.
Methods
Summary of the approach
The impact of the proposed specialist heart failure services
was defined as the sum of the impact of three constituent
non-invasive effective interventions: spironolactone, b-
blockers (in the form of carvedilol) and N-LEI. Carvedilol
was chosen because it is one of the two such b-blockers
currently licensed for use in heart failure in the UK [28],
and the one most commonly used [14]. For heart failure
patients with history of previous hospitalisation who were
eligible but untreated the potential impact on all cause
readmissions and mortality associated with optimal treat-
ment uptake during one year was calculated. The impact
of examined treatments on other outcomes, such as qual-
ity of life, was not calculated due to lack of appropriate
baseline data.
The potential impact of other treatments (e.g. ACE inhib-
itors or A2 antagonists, and also aspirin and statins for
patients with heart failure due to coronary heart disease)
was excluded from the calculations, as their delivery is
much less dependent on specialist services and because
pre-existing high local uptake meant that the potential for
incremental improvement was negligible (see Results).
Analysis was restricted to heart failure patients with previ-
ous hospitalisation because although patients in an early
disease stage may also use a heart failure specialist service,
they were judged not to represent its primary target.
Basic modelling formula
The annual potential impact of an intervention was calcu-
lated using an adaptation of previously described meth-
ods [23,24]. The number of prevented or postponed
events for treatment a (PPEa) is calculated as:
PPEa = n * Pe-u(a) * re-u(a) * RRR(a)BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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where: n = number of patients with condition of interest,
Pe-u(a)  = proportion of patients that are eligible but
untreated, re-u(a) = probability of event (or mean number
of events per patient) per eligible but untreated patient
during study period, and RRR(a) = relative risk reduction
associated with treatment (where RRR(a) = 1 - RR(a)). The
potential impact was calculated for one year [23,24].
The proportion of patients that are eligible but untreated
(Pe-u) equals the proportion of eligible (Pe) minus the pro-
portion of patients already treated (Pt). Treatment eligibil-
ity is defined as the absence of contraindication or
intolerance, or Pe = 1 - (Pci + Pint), where Pci denotes the
proportion of patients with a contra-indication, and Pint
the proportion of patients with treatment intolerance
[23]. This means that the proportion of patients that can
be expected to have either a known contraindication to
treatment (e.g. pre-existent renal impairment in relation
to spironolactone treatment) or treatment intolerance due
to side effects are by definition excluded from the propor-
tion of patients that are "eligible but untreated".
The value of re-u(a) is rarely available from observational
data sources which usually provide information about
event rates (or mean number of events per patient) in the
"total" patient population, independently of treatment
status (rtotal). However, when the proportion of treated
patients is small or nears zero, using values of rtotal to
approximate re-u(a) is reasonable, and this approach was
used in this paper. It is acknowledged that it is theoreti-
cally possible to calculate the value of re-u(a) as a function
of rtotal, if the proportion treated and untreated are known
(e.g. from audit): re-u(a) = rtotal / [Pu(a) + (Pt(a) * RRR(a))],
where Pu(a) = proportion untreated and Pt(a) = proportion
treated and RRR(a) = the relative risk reduction for the
treatment  a. However such a calculation assumes that
untreated patients do not include those ineligible due to
contraindication or intolerance, and therefore has the
potential to introduce error, particularly in the case of rel-
atively small sample sizes.
The value of n * Pe-u represents the target number of
"patients-to-be-treated", through improvement in the qual-
ity of provided care. The value of n * re-u represents the
number of "expected events" among all patients with the
condition of interest.
Data sources used in modelling
The annual mean value of n was calculated from the study
hospital Hospital Episodes Statistics (HES) data for the
three financial years period 1998–2001, relating to
patients with an emergency medical admission due to
heart failure primary diagnosis (ICD code: I50.0–I50.9)
discharged alive. We restricted data to patients with heart
failure as primary diagnosis (i.e. coded in the first posi-
tion) as opposed to any secondary diagnoses.
For the proportion of treated patients, and also for the
proportion of patients with a treatment contraindication,
local audit data (Appendix 1) were applied to the study
population. In the absence of local data, for spironolac-
tone and carvedilol respectively, treatment intolerance
was taken to represent either the proportion of patients in
the treatment arm of RALES [10] who discontinued treat-
ment due to adverse events, or the proportion of patients
in the treatment arm of COPERNICUS [29] who withdrew
from treatment during the first 8 weeks (Table 1). Clearly
there was no pharmacological intolerance related to N-
LEI, but Pint was used for consistency to denote the pro-
portion of patients declining the intervention. In the
absence of such estimate from published studies a value
for Pint was imputed, based on the assumption that given
the non-invasive nature of the intervention it was unlikely
to be worse than that reported for the two pharmacologi-
cal therapies (Table 1).
The rtotal value for death was derived by data-linking the
HES data (on hospitalised patients with heart failure pri-
mary diagnosis) with Office for National Statistics mortal-
ity data (three financial year average 1998–2001). The
rtotal value for the mean number of all cause readmissions
per patient was derived from HES data analysis (three
financial years average 1998–2001). As explained, these
values were used as approximates for the values of re-u.
Table 1: "Patients-to-be-treated " by type of treatment, based on proportion of patients with a contraindication and intolerance (n = 
286)
Proportion with contra-
indication (Pci)
Prop. intolerant (Pint) Proportion eligible 
Pe = 1 - (Pci + Pint)
Proportion already 
treated (Pt)
Pe-u (= Pe - Pt) Incremental number 
of "patients-to-be-
treated" (= n * Pe-u)
Spironolactone 0.08* (95% CI 0.04–0.15) 0.08 [10] (95% CI 0.06–0.1) 0.84 0.25* (95% CI 0.18–0.34) 0.59 169
b-blockers 0.2* (95% CI 0.13–0.28) 0.052 [29] (95% CI 3.9–6.5) 0.748 0.12* (95% CI 0.07–0.19) 0.628 180
N-LEI 0* 0.15** 0.85 0 0.85 243
*Estimates from local audit data **Based on informed judgment-see methodsBMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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RRR values for all-cause readmissions (from now on:
readmissions) and all-cause mortality (from now on:
mortality) were obtained from RALES (spironolactone)
[10], COPERNICUS (carvedilol) [30,31] and McAlister et
al. (N-LEI) [11]. A RRR value for the effect of spironolac-
tone on readmissions was not originally reported, there-
fore this was estimated from data presented in tables of
the original publication [10]. RRR values were assumed to
be time-independent and applied to a year-period
[23,24]. The effect (RRR) of spironolactone and carvedilol
is independent of sex, age and heart failure disease stage
[10,30,31] and such independence was assumed for N-LEI
based on relevant suggestions in the literature [32,33].
Modelling of patient eligibility for combined treatment
Spironolactone, b-blockers and N-LEI may be used in
combination in eligible patients. As for other cardiovascu-
lar treatments [21,22,34], an independent cumulative
effect of different interventions can be assumed, and the
combined relative risk (RRR) calculated as originally pro-
posed by Mant and Hicks [35].
(RRRa+b...) = 1 - (RRRa) * (RRRb) * ....
where a, b ... different interventions, and a+b... combined
interventions.
Therefore the expected health impact was calculated in
three ways. First for each of the interventions offered in
isolation (Model 1). Second, assuming an independent
but combined effect for the two pharmacological inter-
ventions (Model 2). Third, assuming an independent but
combined effect for all three interventions, including N-
LEI (Model 3). The latter assumes that the mechanism by
which N-LEI reduces readmissions is through life-style
modification rather than improvement in compliance
with pharmacological therapies such as spironolactone
and b-blockers. This is a reasonable assumption in rela-
tion to sprionolactone and b-blockers in particular, since
the great majority of patients included in reported N-LEI
trials did not receive either of these two drugs, due to lack
of evidence about the effectiveness of these treatments at
the time the studies were performed. For example, less
than 10% of patients received b-blockers in the most
recently reported N-LEI trial [5].
As spironolactone, b-blockers and N-LEI have different
contraindication and intolerance profiles, it was assumed
that eligibility for any one intervention is independent of
any other. Formulae based on simple probability theory
were therefore used to calculate the number of patients
who can be expected to be eligible for none, one, two or
three interventions (Appendix 2).
Confidence intervals, sensitivity analysis
For all reported proportions exact binomial 95% confi-
dence intervals (CI) were calculated. To examine the
robustness of the modelling, and to also simulate the
impact of examined interventions in alternative settings,
estimates of individual variables used in the modelling
were varied sequentially, using data from alternative set-
tings, or, in the absence of empirical data, based on rea-
sonable assumptions.
Results
Among 286 patients (95%CI: 250–320) expected to be
discharged alive following a heart failure hospitalisation
during one year, the percentage of eligible but untreated
patients was 59% for spironolactone, 63% for carvedilol
and 85% for N-LEI (Table 1). The crude uptake of aspirin
or warfarin, statins and ACE inhibitors or A2 antagonists
among audited patients was 73%, 88% and 79%
respectively.
Using local data (see Methods), the annual risk of death
among all heart failure patients discharged alive (inde-
pendently of treatment status) was 32% (95%CI: 29–
35%) and the annual mean number of readmissions per
patient was 0.54 (95% CI: 0.44–0.63).
The respective RRR for readmission and mortality used
were 18% (CI impossible to calculate without access to
raw data) and 30% (95%CI: 18–40%) for spironolactone
[10]; and 20% (CI not reported in original publication, p
value = 0.002) [31] and 35% (95%CI: 19–48) [30] for
carvedilol. For N-LEI the RRR for readmission was 23%
(95%CI: 14–32%), however it was not possible to use a
RRR value for the effect on mortality, as no such signifi-
cant effect is reported in the literature [RRR 0.06 (95% CI:
-0.19–0.25)] [11].
Impact on annual mortality and readmissions by individual 
or combined treatment
Optimal uptake of spironolactone during one year among
all eligible but untreated patients would prevent or post-
pone 16 readmissions and 16 deaths (or 11% of all
expected readmissions and 18% of all expected deaths).
The corresponding numbers for carvedilol are 19 readmis-
sions and 20 deaths (or 13% of all expected readmisisons
and 22% of all expected deaths); and for N-LEI 30
readmissions (or 20% of all expected readmissions) and
an uncertain number of deaths (Model 1, Table 2 (see
Additional file 1) and Figure 1). Optimal uptake of
spironolactone and carvedilol in combination during one
year among all eligible but untreated patients would pre-
vent or postpone 34 readmissions and 33 deaths (or 22%
of all expected readmissions and 36% of all expected
deaths) [Model 2, Table 2 (see Additional file 1)]. Opti-
mal uptake of spironolactone, b-blockers and N-LEI inBMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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combination during one year among all eligible but
untreated patients would prevent or postpone 57 hospi-
talisations and a minimum of 33 deaths (or 37% of all
expected readmissions and a minimum of 36% of all
expected deaths) [Model 3, Table 2 (see Additional file 1)]
-the impact on deaths may be higher as there is uncer-
tainty about a true effect of N-LEI on mortality. Compara-
tively, spironolactone, carvedilol and N-LEI in
combination would prevent or postpone about four times
as many readmissions and a minimum of twice as many
deaths due to all causes compared to spironolactone ther-
apy alone.
Sensitivity analysis
Optimal uptake of combined treatment with spironolac-
tone, carvedilol and N-LEI during one year among all eli-
gible but untreated patients generally changed little with
variation of individual components of the modelling
equation, informed by data relating to alternative settings,
or, in the absence of such information, on reasonable
assumptions (Table 2). The exception was in relation to
estimates of readmissions prevented or postponed, due to
a large difference between literature-based estimates [5]
and those observed in the study setting.
Potential impact of optimal uptake of interventions (S = spironolactone, C = Carvedilol, N-LEI = Nurse-Led Educational  Intervention) Figure 1
Potential impact of optimal uptake of interventions (S = spironolactone, C = Carvedilol, N-LEI = Nurse-Led Educational 
Intervention)
16
20
0
33 33
16
19
30
34
57
0.14
0.17
0.26
0.30
0.50
0
10
20
30
40
50
60
Spironolactone Carvedilol Nurse-led
educational
intervention
Optimal
combined S+C
Optimal
combined
S+C+N-LEI
Intervention
N
u
m
b
e
r
 
o
f
 
p
r
e
v
e
n
t
e
d
 
o
r
 
p
o
s
t
p
o
n
e
d
 
e
v
e
n
t
s
0.00
0.10
0.20
0.30
0.40
0.50
0.60
%
 
o
f
 
a
l
l
 
h
o
s
p
i
t
a
l
 
a
d
m
i
s
s
i
o
n
s
Deaths
Readmissions
% of all hospital
admissionsBMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
Page 6 of 10
(page number not for citation purposes)
Discussion
Specialist heart failure services offered to patient popula-
tions with previous low uptake of b-blockers and no pre-
vious uptake of N-LEI can potentially help prevent or
postpone approximately four times as many readmissions
and at least twice as many deaths compared with optimi-
sation of uptake of interventions not necessarily requiring
specialist services such as spironolactone. The seemingly
small impact in terms of overall hospital admissions bur-
den should be examined in the context of increasing
demand for emergency medical care, and the paucity of
evidence on the preventability of medical readmissions in
general [36,37]. The findings therefore provide evidence
for establishing specialist services for heart failure patients
with a history of previous hospitalisation in healthcare
settings currently with low uptake of b-blockers and with-
out provision of N-LEI. They also illustrate a method by
which accurate and timely local health information could
support local decision-making about the introduction of
evidence-based interventions.
Although the cost-effectiveness of specialist heart failure
services was not examined in this study, impact assess-
ment could inform further economic analysis [24]. While
we have not attempted a cost-effectivenes analysis, this
would be an important future endeavour. The costs relat-
ing to implementing N-LEI, and also prescribing costs,
will have to be balanced against the improved health out-
comes. The prevalence of heart failure appears to be
increasing in the population, and cost estimates associ-
ated with its optimal management are important.
At present in the UK there is a lack of population-based
data about the uptake of heart failure interventions. How-
ever the majority of the UK population is not covered by
specialist heart failure services and population treatment
uptake of b-blockers and N-LEI in particular is thought to
be very low. Therefore, although the present study relates
to only one setting, and the study hospital only covers
about 0.5% of the total UK population, the findings may
currently (2004) be applicable to many other UK settings,
and the number of deaths and readmissions that can be
prevented or postponed at a national (UK) level may be
much greater. A larger study, using data from multiple
hospital settings on outcomes, and treatment uptake and
contraindication rates, would be desirable. A nationally
co-ordinated audit of heart failure care, similar to the one
for management of acute myocardial infarct [38] will be
helpful, as a means to not only monitor improvement in
care but also to inform impact assessment of various treat-
ments and, subsequently, planning of services.
Incremental rather than absolute health benefits relating
to interventions were calculated, as in practice, incremen-
tal change is most important in decision-making. Esti-
mates of incremental health impact are subject to the
variation in current treatment uptake, as both the absolute
and relative (i.e. in relation to alternative interventions)
health impact of an intervention will vary if the treatment
uptake of the same or other interventions change. An
example of this notion, in relation to varying levels of b-
blocker uptake in different settings, has informed sensitiv-
ity analysis. Similarly, in settings already delivering N-LEI
the potential incremental impact of this intervention will
be smaller.
Locally derived estimates of risk of death and mean
number of readmissions per patient usually relate to the
survival and readmission experience of all patients, inde-
pendently of treatment uptake status. Such estimates (i.e.
Table 3: Sensitivity analysis estimates of events prevented or postponed by factor, varied sequentially
Varied factor Original estimate (source) Varied estimate (source) New estimate of number of 
deaths prevented or 
postponed (% change from 
previous "best" estimate-33)
New estimate of number of 
readmissions prevented or 
postponed (% change from 
previous "best" estimate-57)
b-blocker uptake 12% (local audit) 34% (ref. [46]) 27 (-18%) 53 (-8%)
b-blocker intolerance 5.2% (ref. [29]) 29% (ref. [4]) 27 (-18%) 52 (-9%)
N-LEI eligibility 85% (informed judgement) 75% (conservative estimate) 33 (0%) 55 (-4%)
Annual risk of death 32% (data-linkage of HES to ONS 
mortality data)
29% (ref. [47]) 30 (-9%) -
Mean number of 
readmissions
0.54 (HES data analysis) 1.41 (ref. [5]) - 150 (+280%)
Estimate of number of 
patients that can benefit 
from treatment
286 (local hospital statistics data) 358 (assuming 25% of of heart 
failure patients are not coded 
with heart failure primary 
diagnosis)
41 (+25%) 72 (+25%)
RRR of all treatments As per references [10,11,30,31] 20% reduction in all estimates 
(assuming that such a reduction 
in effectiveness might be 
applicable due to overall reduced 
baseline risk compared to that 
reported in original trials)
27 (-19%) 47 (-20%)
HES: Hospital Episodes Statistics; ONS: Office for National Statistics; Ref.: Reference RRR: Relative Risk ReductionBMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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rtotal, to approximate re-u) can still be used to assess the
incremental impact of interventions [23], particularly if
the proportion of patients previously receiving the inter-
vention(s) of interest is small (e.g. in this study 0% –
25%). As generally untreated patients have a higher prob-
ability of death or readmission the resulting values most
likely under- rather than over-estimate the calculated
expected impact.
Direct empirical evidence about the combined effect of
the interventions examined by our study is limited,
although reassuringly a similar effect size of spironolac-
tone is reported in the minority (11%) of the RALES par-
ticipants who also received b-blockers [10]. It is likely that
the impact on readmissions of maximizing uptake of
spironolactone has been under-estimated by this study,
as, without access to the RALES raw data, the RRR value
used was not based on "time-to-event" analysis. The
assumption that the effect of N-LEI is independent of the
effect of spironolactone and b-blockers is reasonable,
since the great majority of patients included in reported
N-LEI trials did not receive either drug, due to lack of evi-
dence about the effectiveness of these treatments at the
time the studies were performed. For example, less than
10% of patients received b-blockers in the most recently
reported N-LEI trial [5]. However, more and better empir-
ical evidence about the combined effect of the examined
heart failure interventions in the future would be
desirable.
The use of hospital statistics data for incidence, survival
and health economic studies has a long tradition in heart
failure epidemiology [2-4,8,39]. Routine data could
potentially both under- and over-estimate the true
number of cases, through "sensitivity" and "specificity"
coding errors. The audit survey provides confidence in
using local routine data, as the "specificity" error was only
7.5%, compared with estimates of about 10% reported in
the literature [40]. An overall high level of accuracy for the
local HES data is indicated by the lack of any obvious
internal validity problems (e.g. lack of any marked varia-
tion between years in relation to admission and readmis-
sion rates) and the concordance with national data on the
proportion of al emergency medical admissions that are
due to heart failure [41], and patients' sex distribution,
and length of stay. In practice it will be difficult for health-
care managers to be able to use anything other than HES
data in their planning considerations. Care should be
given when planning services for specific local settings in
using activity data relating to periods longer than one-year
(e.g. three years), to reduce random variation of activity,
as in the current study.
The modelled figure of 286 patients per year relates to
heart failure patients that have been discharged alive, hav-
ing discounted for in-hospital deaths occurring among
patients with primary diagnosis of heart failure. In Scot-
land, during the period 1990–1995, the mean number of
admissions independently of discharge status (dead or
alive) was 341 in large teaching hospitals and 244 in large
general hospitals -possibly of similar type to Stockport
NHS Trust [42]. Therefore the number of patients mod-
elled in our study is of the expected order compared to the
literature. We have opted to use data relating to patients
with "primary" diagnosis of heart failure, as nationally in
the UK and in the literature [2,3,8,15,41,42], the use of
primary diagnosis is well-established for estimates of
heart failure disease burden, and local policy makers will
be familiar with such use of the data. We have however
addressed the potential for under-estimation of true dis-
ease burden, and, subsequently, the potential underesti-
mation of the impact of modelled interventions through
sensitivity analysis. It has to be noted that the actual level
of activity does not affect the proportional order of the
impact associated with each individual intervention and
that of treatment combinations.
Calculations assume treatment continuity among eligible
patients during one year. In reality it would be impossible
to review all heart failure patients with previous hospital-
isation in specialist clinics perpetually, and in order to
sustain treatment uptake the role of primary (non-special-
ist) care is crucial. Similarly, heart failure patients without
prior hospitalisation (e.g. in early disease stage) may in
practice be referred to specialist services and benefit from
them. The associated impact of services in relation to this
patient population was not calculated. Such an
assessment may however be constrained by limited evi-
dence of effectiveness of N-LEI in heart failure patients
without prior hospitalisation, and by the difficulty (in the
absence of accurate and timely information from popula-
tion-based registries) of obtaining realistic estimates of
annual risk of death and number of expected hospitalisa-
tions per patient. It is important to notice that the location
of a specialist heart failure service can be either in second-
ary or primary care.
Calculated impact estimates assume a one-year period for
a specific cohort of patients from a point in time. This
number is unlikely to remain the same over time due to
attrition of the cohort and changes in treatment levels and
baseline risk. However, in any given setting, the popula-
tion of heart failure patients is a dynamic one and is sub-
ject to variation in number, and also secular trends in
treatment levels and baseline risk of mortality and
readmission. Therefore, in subsequent years, new esti-
mates would be required to allow for these changes over
time.BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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We have estimated benefits of treatments in this study
exclude the proportion of patient with either a contraindi-
cation or treatment intolerance (see Methods, "Basic
modelling formula used"). In practice, a patient with a
recognised contraindication to a given treatment might
adversely be prescribed that treatment, resulting in harm.
Similarly, in clinical practice treatment intolerance pre-
supposes exposure to treatment, which might also be
harmful. Ideally future healthcare impact assessment
studies should attempt calculation of potential harm, as
well as expected benefit.
Conclusion
In a population of previously hospitalised patients with
low previous uptake of b-blockers and no uptake of N-LEI,
optimal combined uptake of interventions through spe-
cialist heart failure services can potentially help prevent or
postpone approximately four times as many readmissions
and at least twice as many deaths compared with simply
optimising uptake of spironolactone (not necessarily
requiring specialist services). Since the publication of the
UK government's coronary heart disease national service
framework [43], regular audit of heart failure treatment is
an explicit component of clinical governance activities in
all NHS hospitals. Routine health data, such as HES and
mortality data, are available at the local (NHS Trust and
Primary Care Trust) level. Open-access web-based
resources, such as Clinical Evidence [44], can be easily used
to help identify effectiveness estimates from the literature.
We suggest that local use of information from audit, rou-
tine administrative data and the literature can help esti-
mate the impact of different heart failure interventions
and inform rational planning of relevant healthcare serv-
ices, as it can provide realistic estimates of expected
outcomes.
Appendix 1. Audit population and methodology
A routine audit survey of heart failure management in the
study hospital conducted by one of the authors (GL) was
used as the source of information for uptake of
spironolactone and b-blockers; also for information on
contraindication rates to spironolactone (i.e. previous
clinical diagnosis of renal failure, or creatinine value
greater than 200 mg/l) and b-blockers (i.e. chronic
obstructive pulmonary disease [COPD], asthma, or heart
block worst than first degree). (Under specialist clinical
supervision it may be possible to treat some HF patients
who also have COPD with b-blockers, however COPD is
a well-recognised contraindication to b-blocker therapy
[15,28]). The records of ninety-nine per cent (199/202) of
all patients with an emergency medical admission due to
heart failure primary diagnosis (ICD code: I50.0–I50.9)
during January and September 2001 were accessed. For
patients with more than one admission during the study
period, only the earliest admission was reviewed. The
accuracy of clinical coding was verified based on echocar-
diography or clinical diagnosis by a consultant physician,
and cases that were miscoded or inaccurately diagnosed in
the first instance were excluded. Patients who according to
the European Society of Cardiology guidelines [45] are
classified as heart failure without Left Ventricular Systolic
Dysfunction (LVSD) (e.g. either atrial fibrillation or heart
valve disease with preserved ventricular function) were
also excluded. Information was collected by records
inspection, including inpatient notes, discharge letters/
prescriptions, echocardiography reports, correspondence
to general practitioners or other hospital consultants, and
follow-up appointment letters or notes. Data collection
on echocardiography findings and the prescription of b-
blockers, was extended to a six-month period after live
discharge. Forty-four (22%) of all inspected cases were
excluded: 14 (7.5%) due to miscoding; 16 (8%) due to
subsequent echocardiography refuting the clinical diag-
nosis; 11 (5.5%) due to having heart failure without
LVSD; and 3 (1.5%) due to missing data. Among the
remaining cases 35 (21.5%) died during the admission
episode and 120 patients were discharged alive. The mean
age of these patients was 77 years, 40% were male, and
57% had heart failure diagnosis based on
echocardiography.
Appendix 2. Calculation of combined treatment 
eligibility
To calculate the number of patients expected to be eligible
for one, two and three treatments in combination: Let
there be 3 groups of size A, B, C indicating the number of
patients eligible for treatments a, b and c respectively out
of a population total T then:
• the number likely to be eligi ble for none of the treat-
ments will be
[(1 - [A/T]) * (1 - [B/T]) * (1 - [C/T]) ] * T
• the number likely to be eligible for treatment "a" alone
will be
[(A/T) * (1 - [B/T]) * (1 - [C/T]) ] * T
and similarly for treatments "b" and "c"
• the number likely to be eligible for treatments "a" and
"b" in combination will be
[(A/T) * (B/T) * (1 - [C/T]) ] * T
and similarly for treatment pairs "b" and "c", and "a" and
"c".BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/10
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• the number likely to be eligible for treatments "a"
and"b" and "c" in combination will be
[(A/T) * (B/T) * (C/T) ] * T
giving a total of eight possible groups. A similar approach
was used for eligibility to two treatments.
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